Advertisement

The Regulation of Clinical Stem Cell Research in China

  • Li Jiang
Chapter
Part of the Stem Cells in Clinical Applications book series (SCCA)

Abstract

Regulating clinical stem cell research, which has been one of the most ethically controversial technologies of the present age, is an unenviable task for China. The ambit of the Administrative Measure is wide. The Chinese government hopes to rein the clinical stem cell research with the enforcement of the new order. However, the legal framework of clinical stem cell therapy leaves a door open for untested and unverified stem cell therapies. And it is still an open question whether the combination of the Ministry of Health and CFDA is capable of enforcing the Administrative Measures on hospitals.

Keywords

Stem Cell Therapy China Policy Regulation 

References

  1. Chen T, Jiang H, Qian W (2011) The funding mode of stem cell research in China. China Basic Sci 4:31Google Scholar
  2. Corrigan O, Liddell K, Mcmillan J, Stewart A Wallace S (2006) Ethical legal and social issues in stem cell research and therapy. Cambridge Genetic Knowledge Park, p 16Google Scholar
  3. Cyranoski D (2015) China announces stem cell rules-long awaited regulations may curb rogue clinics offering unproven treatments. Nature. http://www.nature.com/news/china-|announces-stem-cell-rules-1.18252. Accessed online 25 Sept 2016
  4. Esteban MA et al (2009) Vitamin C enhances the generation of mouse and human induced pluripotent stem cells. Cell Stem Cell 6:71CrossRefPubMedGoogle Scholar
  5. Guotong X (2007) The challenge and opportunity of stem cell research in China. Front Sci 4:36Google Scholar
  6. Jiang L (2016a) Regulating human embryonic stem cell in China: a comparative study on human embryonic stem cell’s patentability and morality in US and EU. Springer, Heidelberg and New YorkCrossRefGoogle Scholar
  7. Jiang L (2016b) Will the first administrative measure on clinical stem cell research end the wild east scientific feast? Biotechnol Law Rep 35(1):27–35CrossRefGoogle Scholar
  8. Robbins-Roth C (2001) From alchemy to IPO: the business of biotechnology. Perseus Publishing, p 91Google Scholar
  9. Song P (2011) The proliferation of stem cell therapies in post-Mao China: problematizing ethical regulation. New Genet Soc 30:141CrossRefGoogle Scholar
  10. The Administrative Measure on Clinical Stem Cell Research in China. (2015). Available at http://www.moh.gov.cn/qjjys/s3581/201508/28635ef99c5743e294f45e8b29c72309.shtml. Last visited 8 Sept 2015
  11. The Ethical Guideline for Biomedical research involving human. (2016). Available at http://www.moh.gov.cn/mohbgt/pw10702/200804/18816.shtml. Last visited 9 Sept 2015
  12. The Ethical Guideline for HESC research in China. (2003). Available at http://www.cncbd.org.cn/News/Detail/3376. Last visited 8 Sept 2015
  13. Watt N (2006) EUROPE reaches deal on stem cell research. The Guardian, LondonGoogle Scholar
  14. Xiaoqin R (2011) The patents granted to Heze Biotechnology. Shanghai Stock NewspaperGoogle Scholar
  15. Yong Y (2011) Beike biotech: win the respect and appraise by the stem cell frontier technology. The Chinese Economic, http://district.ce.cn/zg/201106/02/t20110602_22458434.shtml. Accessed 20 Nov 2013
  16. Zhao XY, Li W, Lv Z, Liu L, Tong M, Hai T, Hao J, Guo CL, Ma QW, Wang L, Zeng F, Zhou Q (2009) iPS cells produce viable mice through tetraploid complementation. Nature 461:7260CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.Kenneth Wang School of LawSoochow UniversitySuzhouChina

Personalised recommendations